These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28158579)

  • 21. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
    Toi M; Shao Z; Hurvitz S; Tseng LM; Zhang Q; Shen K; Liu D; Feng J; Xu B; Wang X; Lee KS; Ng TY; Ridolfi A; Noel-Baron F; Ringeisen F; Jiang Z
    Breast Cancer Res; 2017 Apr; 19(1):47. PubMed ID: 28399902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
    Turner N; Dent RA; O'Shaughnessy J; Kim SB; Isakoff SJ; Barrios C; Saji S; Bondarenko I; Nowecki Z; Lian Q; Reilly SJ; Hinton H; Wongchenko MJ; Kovic B; Mani A; Oliveira M
    Breast Cancer Res Treat; 2022 Feb; 191(3):565-576. PubMed ID: 34860318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
    O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
    JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
    Gamucci T; Mentuccia L; Natoli C; Sperduti I; Cassano A; Michelotti A; Di Lauro L; Sergi D; Fabi A; Sarobba MG; Marchetti P; Barba M; Magnolfi E; Maugeri-Saccà M; Rossi E; Sini V; Grassadonia A; Pellegrini D; Astone A; Nisticò C; Angelini F; Vaccaro A; Pellegrino A; De Angelis C; Palleschi M; Moscetti L; Bertolini I; Buglioni S; Giordano A; Pizzuti L; Vici P
    J Cell Physiol; 2017 Jun; 232(6):1571-1578. PubMed ID: 27861874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
    Ozaki Y; Tsurutani J; Mukohara T; Iwasa T; Takahashi M; Tanabe Y; Kawabata H; Masuda N; Futamura M; Minami H; Matsumoto K; Yoshimura K; Kitano S; Takano T
    Eur J Cancer; 2022 Aug; 171():193-202. PubMed ID: 35728379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
    Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
    JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    Petitjean A; Smith-Palmer J; Valentine W; Tehard B; Roze S
    BMC Cancer; 2019 Feb; 19(1):140. PubMed ID: 30744578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
    Miles DW; de Haas SL; Dirix LY; Romieu G; Chan A; Pivot X; Tomczak P; Provencher L; Cortés J; Delmar PR; Scherer SJ
    Br J Cancer; 2013 Mar; 108(5):1052-60. PubMed ID: 23422754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.
    Zhao M; Pan X; Layman R; Lustberg MB; Mrozek E; Macrae ER; Wesolowski R; Carothers S; Puhalla S; Shapiro CL; Ramaswamy B
    Invest New Drugs; 2014 Dec; 32(6):1285-94. PubMed ID: 24894652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.
    Diéras V; Campone M; Yardley DA; Romieu G; Valero V; Isakoff SJ; Koeppen H; Wilson TR; Xiao Y; Shames DS; Mocci S; Chen M; Schmid P
    Ann Oncol; 2015 Sep; 26(9):1904-1910. PubMed ID: 26202594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
    Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Vuylsteke P; Huizing M; Petrakova K; Roylance R; Laing R; Chan S; Abell F; Gendreau S; Rooney I; Apt D; Zhou J; Singel S; Fehrenbacher L
    Ann Oncol; 2016 Nov; 27(11):2059-2066. PubMed ID: 27573562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
    Martín M; Chan A; Dirix L; O'Shaughnessy J; Hegg R; Manikhas A; Shtivelband M; Krivorotko P; Batista López N; Campone M; Ruiz Borrego M; Khan QJ; Beck JT; Ramos Vázquez M; Urban P; Goteti S; Di Tomaso E; Massacesi C; Delaloge S
    Ann Oncol; 2017 Feb; 28(2):313-320. PubMed ID: 27803006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.
    Cannita K; Paradisi S; Cocciolone V; Bafile A; Rinaldi L; Irelli A; Lanfiuti Baldi P; Zugaro L; Manetta R; Alesse E; Ricevuto E; Ficorella C
    Cancer Med; 2016 Sep; 5(9):2232-9. PubMed ID: 27416882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
    Smith IE; Pierga JY; Biganzoli L; Cortés-Funes H; Thomssen C; Pivot X; Fabi A; Xu B; Stroyakovskiy D; Franke FA; Kaufman B; Mainwaring P; Pienkowski T; De Valk B; Kwong A; González-Trujillo JL; Koza I; Petrakova K; Pereira D; Pritchard KI;
    Ann Oncol; 2011 Mar; 22(3):595-602. PubMed ID: 20819780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
    Robert NJ; Saleh MN; Paul D; Generali D; Gressot L; Copur MS; Brufsky AM; Minton SE; Giguere JK; Smith JW; Richards PD; Gernhardt D; Huang X; Liau KF; Kern KA; Davis J
    Clin Breast Cancer; 2011 Apr; 11(2):82-92. PubMed ID: 21569994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.
    Yamada H; Inoue K; Nagai SE; Nakai M; Arisawa F; Ueda H; Saito T; Ninomiya J; Kuroda T; Sakurai T; Kodama H; Kimizuka K; Hata S; Kai T; Kurosumi M;
    J Nippon Med Sch; 2017; 84(5):215-223. PubMed ID: 29142182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    Miller K; Wang M; Gralow J; Dickler M; Cobleigh M; Perez EA; Shenkier T; Cella D; Davidson NE
    N Engl J Med; 2007 Dec; 357(26):2666-76. PubMed ID: 18160686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.